0001209191-19-003115.txt : 20190109 0001209191-19-003115.hdr.sgml : 20190109 20190109174952 ACCESSION NUMBER: 0001209191-19-003115 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190104 FILED AS OF DATE: 20190109 DATE AS OF CHANGE: 20190109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: AYRES JOHN C CENTRAL INDEX KEY: 0001763067 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35952 FILM NUMBER: 19518915 MAIL ADDRESS: STREET 1: C/O ARATANA THERAPEUTICS, INC. STREET 2: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 CITY: LEAWOOD STATE: KS ZIP: 66211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARATANA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001509190 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383826477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 CITY: LEAWOOD STATE: KS ZIP: 66211 BUSINESS PHONE: 913.353.1000 MAIL ADDRESS: STREET 1: 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 CITY: LEAWOOD STATE: KS ZIP: 66211 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2019-01-04 0 0001509190 ARATANA THERAPEUTICS, INC. PETX 0001763067 AYRES JOHN C C/O ARATANA THERAPEUTICS, INC. 11400 TOMAHAWK CREEK PARKWAY, SUITE 340 LEAWOOD KS 66211 0 1 0 0 SEE REMARKS Common Stock 98091 D Stock Option (Right to Buy) 20.40 2023-11-12 Common Stock 66667 D Stock Option (Right to Buy) 18.42 2024-01-12 Common Stock 20000 D Stock Option (Right to Buy) 17.18 2025-01-28 Common Stock 25000 D Stock Option (Right to Buy) 3.14 2026-01-21 Common Stock 70000 D Stock Option (Right to Buy) 8.02 2027-01-12 Common Stock 37500 D Stock Option (Right to Buy) 4.83 2028-01-24 Common Stock 60000 D Fully vested as of November 13, 2017. Fully vested as of January 13, 2018. Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2016 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2019, subject to continued service with the Issuer through the applicable vesting dates. Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2017 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2020, subject to continued service with the Issuer through the applicable vesting dates. Vested as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2018 and vested or will vest, as applicable, as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2021, subject to continued service with the Issuer through the applicable vesting dates. Vests as to 25% of the total number of shares (rounded down to the nearest whole share) on January 29, 2019 and as to an additional 1/48th of the total number of shares (rounded down to the nearest whole share) on the same day of each of the 36 successive calendar months thereafter, such that the stock option shall be vested as to all shares on January 29, 2022, subject to continued service with the Issuer through the applicable vesting dates. The Reporting Person is VP - Corporate Operations, General Counsel and Secretary. /s/ John C. Ayres 2019-01-09 EX-24.3_826094 2 poa.txt POA DOCUMENT POWER OF ATTORNEY John C. Ayres With respect to holdings of and transactions in securities issued by Aratana Therapeutics, Inc. (the "Company"), the undersigned hereby constitutes and appoints the individuals named on Schedule A attached hereto and as may be amended from time to time, or any of them signing singly, with full power of substitution and resubstitution, to act as the undersigned's true and lawful attorney-in-fact to: 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC; 2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder; 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-facts discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution and resubstitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorneys-in-fact substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is any Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of January, 2019. /s/ John C. Ayres John C. Ayres Schedule A Individuals Appointed as Attorney-in-Fact with Full Power of Substitution and Resubstitution 1. Steven St. Peter, M.D., President and Chief Executive Officer 2. Craig Tooman, Chief Financial Officer